Sign In
Buy SPRC
$6.97
-0.440 (-5.94%)
At Close: Jun 22, 2026
SciSparc Announces 1-for-9 Reverse Share Split
08:00am, Monday, 02'nd Mar 2026
Following the reverse share split, the Company will have approximately 565,000 outstanding shares, out of which approximately 561,533 will be publicly held Tel Aviv, Israel, March 02, 2026 (GLOBE NEWS
SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA
08:24am, Monday, 02'nd Feb 2026
NeuroThera's Proprietary Cannabinoid-Enhanced Platform Targets Antibiotic Resistance Using Approved Antimicrobials TEL AVIV, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“
Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA
08:00am, Monday, 02'nd Feb 2026
Proprietary Cannabinoid-Enhanced Platform Targets Antibiotic Resistance Using Approved Antimicrobials February 2, 2026 – TheNewswire - Vancouver, British Columbia, Canada- Neurothera Labs Inc. (TSXV
SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization
08:13am, Monday, 26'th Jan 2026
SciSparc intends to target the global multi- billion dollar GERD device market TEL AVIV, Israel, Jan. 26, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a com
SciSparc intends to commence commercialization of these patented technologies immediately following the transaction closing
SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance
04:02pm, Monday, 12'th Jan 2026
TEL AVIV, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority
Neurothera Labs Announces Results of AGM
06:00pm, Thursday, 08'th Jan 2026
January 8, 2026 – TheNewswire - Vancouver, British Columbia, Canada – Neurothera Labs Inc. (TSXV: NTLX) (“ Neurothera ” or the “ Company ”), a clinical-stage biotech company and a majority
TEL AVIV, Israel, Dec. 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-st
December 30, 2025 – TheNewswire - Vancouver, British Columbia, Canada - Neurothera Labs Inc. (TSXV: NTLX) ( “ Neurothera ” or the “ Company ”), a clinical-stage biotech company and a majorit
SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company
09:29am, Tuesday, 02'nd Dec 2025
TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-s
Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company
08:05am, Tuesday, 02'nd Dec 2025
December 2, 2025 – TheNewswire - Vancouver, British Columbia, Canada - Neurothera Labs Inc. (TSXV: NTLX) (“ Neurothera” or the “ Company”), a clinical-stage biotech company and a majority-
SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio
08:32am, Monday, 01'st Dec 2025
TEL AVIV, Israel, Dec. 01, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority
SciSparc (NASDAQ:SPRC) Shares Down 2.8% – Time to Sell?
03:22am, Saturday, 29'th Nov 2025
SciSparc Ltd. (NASDAQ: SPRC - Get Free Report) shares were down 2.8% during mid-day trading on Friday. The company traded as low as $2.07 and last traded at $2.1570. Approximately 432,494 shares were
SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems
07:38am, Wednesday, 26'th Nov 2025
TEL AVIV, Israel, Nov. 26, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority
TEL AVIV, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-st
